127 related articles for article (PubMed ID: 38461767)
1. Population-based survival rates after curative surgical and non-surgical treatment of stage III NSCLC since 2017.
Damhuis RAM; Dickhoff C; Bahce I; Senan S
Lung Cancer; 2024 Apr; 190():107532. PubMed ID: 38461767
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer.
Sher DJ; Fidler MJ; Liptay MJ; Koshy M
Lung Cancer; 2015 Jun; 88(3):267-74. PubMed ID: 25862147
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
4. Real-World Treatment of Stage III NSCLC: The Role of Trimodality Treatment in the Era of Immunotherapy.
Moore S; Leung B; Wu J; Ho C
J Thorac Oncol; 2019 Aug; 14(8):1430-1439. PubMed ID: 31002953
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
Criss SD; Mooradian MJ; Sheehan DF; Zubiri L; Lumish MA; Gainor JF; Reynolds KL; Kong CY
JAMA Oncol; 2019 Mar; 5(3):358-365. PubMed ID: 30543349
[TBL] [Abstract][Full Text] [Related]
6. Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02).
Hasegawa T; Ariyasu R; Tanaka H; Saito R; Kawashima Y; Horiike A; Sakatani T; Tozuka T; Shiihara J; Saiki M; Tambo Y; Sonoda T; Miyazaki A; Uematsu S; Tsuchiya-Kawano Y; Yanagitani N; Nishino M
Cancer Chemother Pharmacol; 2023 Jul; 92(1):29-37. PubMed ID: 37243795
[TBL] [Abstract][Full Text] [Related]
7. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.
Senan S; Özgüroğlu M; Daniel D; Villegas A; Vicente D; Murakami S; Hui R; Faivre-Finn C; Paz-Ares L; Wu YL; Mann H; Dennis PA; Antonia SJ
ESMO Open; 2022 Apr; 7(2):100410. PubMed ID: 35247871
[TBL] [Abstract][Full Text] [Related]
8. Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.
Fukui T; Hosotani S; Soda I; Ozawa T; Kusuhara S; Kakegawa MI; Kasajima M; Hiyoshi Y; Igawa S; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Ishiyama H; Naoki K
Thorac Cancer; 2020 Apr; 11(4):1005-1014. PubMed ID: 32057187
[TBL] [Abstract][Full Text] [Related]
9. Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer.
Chu CH; Chiu TH; Wang CC; Chang WC; Huang AC; Liu CY; Wang CL; Ko HW; Chung FT; Hsu PC; Guo YK; Kuo CS; Yang CT
Thorac Cancer; 2020 Jun; 11(6):1541-1549. PubMed ID: 32281272
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of salvage resection following locoregional failure after chemoradiotherapy and consolidation durvalumab for unresectable stage III non-small cell lung cancer.
Dickhoff C; Unal S; Heineman DJ; Winkelman JA; Braun J; Bahce I; van Dorp M; Senan S; Dahele M
Lung Cancer; 2023 Aug; 182():107294. PubMed ID: 37442060
[TBL] [Abstract][Full Text] [Related]
11. Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec.
Agulnik J; Kasymjanova G; Pepe C; Hurry M; Walton RN; Sakr L; Cohen V; Lecavalier M; Small D
Curr Oncol; 2020 Oct; 27(5):e459-e466. PubMed ID: 33173385
[TBL] [Abstract][Full Text] [Related]
12. Importance of tumour volume and histology in trimodality treatment of patients with Stage IIIA non-small cell lung cancer-results from a retrospective analysis.
Joosten PJM; Dickhoff C; van der Noort V; Smeekens M; Numan RC; Klomp HM; van Diessen JNA; Belderbos JSA; Smit EF; Monkhorst K; Oosterhuis JWA; van den Heuvel MM; Dahele M; Hartemink KJ
Interact Cardiovasc Thorac Surg; 2022 Mar; 34(4):566-575. PubMed ID: 34734237
[TBL] [Abstract][Full Text] [Related]
13. Treatment-related pulmonary adverse events induced by chemoradiation and Durvalumab affect survival in locally advanced non-small cell lung cancer.
Xu T; Wu L; Gandhi S; Jing W; Nguyen QN; Chen A; Chang JY; Nurieva R; Sheshadri A; Altan M; Lee PP; Lin SH; Liao Z
Radiother Oncol; 2022 Nov; 176():149-156. PubMed ID: 36209942
[TBL] [Abstract][Full Text] [Related]
14. Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study).
Jung HA; Sun JM; Lee SH; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2020 Aug; 146():112-119. PubMed ID: 32526601
[TBL] [Abstract][Full Text] [Related]
15. Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study.
Horinouchi H; Atagi S; Oizumi S; Ohashi K; Kato T; Kozuki T; Seike M; Sone T; Sobue T; Tokito T; Harada H; Maeda T; Mio T; Shirosaka I; Hattori K; Shin E; Murakami H
Cancer Med; 2020 Sep; 9(18):6597-6608. PubMed ID: 32730697
[TBL] [Abstract][Full Text] [Related]
16. Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).
Socinski MA; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Hui R; Gray JE; Park K; Vincent M; Mann H; Newton M; Dennis PA; Antonia SJ
Clin Lung Cancer; 2021 Nov; 22(6):549-561. PubMed ID: 34294595
[TBL] [Abstract][Full Text] [Related]
17. Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab.
Jazieh K; Khorrami M; Saad A; Gad M; Gupta A; Patil P; Viswanathan VS; Rajiah P; Nock CJ; Gilkey M; Fu P; Pennell NA; Madabhushi A
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35256515
[TBL] [Abstract][Full Text] [Related]
18. Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013.
Dickhoff C; Dahele M; de Langen AJ; Paul MA; Smit EF; Senan S; Hartemink KJ; Damhuis RA
J Thorac Oncol; 2016 Apr; 11(4):566-72. PubMed ID: 26773741
[TBL] [Abstract][Full Text] [Related]
19. Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition.
Unterrainer M; Taugner J; Käsmann L; Tufman A; Reinmuth N; Li M; Mittlmeier LM; Bartenstein P; Kunz WG; Ricke J; Belka C; Eze C; Manapov F
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1407-1416. PubMed ID: 34664091
[TBL] [Abstract][Full Text] [Related]
20. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
Patel JD; Lee JW; Carbone DP; Wagner H; Shanker A; de Aquino MTP; Horn L; Johnson ML; Gerber DE; Liu JJ; Das MS; Al-Nsour MA; Dakhil CSR; Ramalingam S; Schiller JH
Clin Lung Cancer; 2020 Nov; 21(6):520-526. PubMed ID: 32807654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
